On Mar. 9, 2021, Luminex announced that it had submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for the company’s new multi-analyte respiratory panel combining Flu A/B and respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target.

This submission represents completion of a key milestone in a Luminex funding award from the Biomedical Advanced Research and Development Authority (BARDA), which helped support the rapid development and validation of the assay.